Maravai LifeSciences Holdings 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Welcome back to the 2026 Stifel Healthcare Conference. Back on the life sciences side, happy to have Maravai with us today. We have Raj Asarpota, CFO, and Jimmy Burnworth, VP of Finance and Sales Operations. Guys, thanks very much for spending some time with us here today.
Thank you, Dan. Appreciate it. I am going to go through a few slides here, then we can pick it up with Q&A.
Yeah. We will be presenting forward-looking statements, so keep that in mind.
To kick it off, Maravai LifeSciences is a leading provider of critical technologies and products that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics, with a particular focus on both nucleic acid production and biosafety testing through our two marquee franchises or brand names, TriLink and Cygnus. TriLink is our diversified genetic medicine platform with three distinct sub-segments. You have mRNA with CleanCap and ModTail as the two franchise products with robust R&D and clinical pipeline, our CDMO service that provides support from discovery to late-stage clinical development, then specialty chemistry, which consists of oligonucleotide synthesis, oligos, NTPs, and consumables. On the Cygnus side, we have a comprehensive portfolio of host cell protein assays, including mass spectrometry and broad-based assays, along with contract services, MockV clearance kits, and custom assays.
Just to point out here, Cygnus HCP kits are used in 31 of 31 commercialized CAR T and cell and gene therapies. A little bit more of a deeper dive into our two reporting segments, Cygnus and TriLink, both that have very different growth dynamics. Starting with TriLink, like I mentioned, that is our genetic medicine platform, accounting for 65% of revenues. Within TriLink, the three buckets, again, as I mentioned previously, mRNA consists of discovery, that is both research and preclinical, GMP, then commercial. As a percent of revenue, that represents 35%, and the five-year expected growth rate there is in the high single digits and low double digits when you fold in commercial revenues expected in 2028 and 2029. CDMO is our contract manufacturing, representing under 10% of revenue and growing at low double digits.
Specialty chemistry, that is oligo synthesis reagents and consumables, is a little bit over 20%, growing at low single digits. TriLink, again, is the flagship that will carry the long-term high growth opportunity for the company, especially as commercial revenue starts to flow in. Cygnus represents 35% of our revenue, growing at mid-single digits, and is the gold standard, steady-eddy, high-margin cash flow business. Looking at TriLink across every stage of mRNA drug development, notwithstanding the spies like us story in the headlines today, we still think NVIDIA is a good analog. The analogy we like to draw is just as NVIDIA does not build AI models, but supplies the compute that every model runs on, similarly, Maravai does not develop the drug, but we supply differentiated technologies and services that hundreds of mRNA and genetic medicine programs are built on.
Walking from left to right here, as we think about the stages of drug development, on the basic research side, we supply CleanCap, ModTail, NTPs, oligos, enzymes, and this is where we seed the market and spur the start of new programs where pricing is not as critical. We want as many programs here to be seeded as possible. Once you move into preclinical, you get a little bit of a scale-up there. Again, CleanCap, ModTail, and GMP enzyme adoption happens here. As you move into clinical, that is where you get a significant step-up in both volume and price as each phase advances. It is critical to point out here that our target for this year was to onboard 10 new GMP customers, which we exceeded, and we are now at just over 50 GMP customers.
Once you get to the commercial stage, you are now significantly scaling CleanCap, and you are also getting the GMP opportunity with ModTail and GMP enzymes, and we think this is a $5 million to a $50 million per program opportunity per year at peak, and I will provide a little bit more detail on that. As we think about clinical phase advancement, again, as each phase advances, it increases our potential revenue per program. As you look at this visual here, the revenue per program, when you are in the preclinical stage, is pretty low, and we think the estimated chances of a program reaching commercialization when it is preclinical are fairly low. But then as you progress into phase I, 10% of those programs have a chance to get to commercial on market. Phase I and phase I-II is about 12% probability.
Phase II is 15%, and then once a program is in phase III, there is a 58%-60% chance that it hits the market. So, we probably weight all of that to help us frame the opportunity for commercial revenue. We look at five different modalities here, and the formula here is you look at each of these modalities, the number of patients per year that would be enrolled in a program, the number of doses that would be administered, the mRNA per dose, and then the price realization impact per unit to assign a value to each of these programs. As you would expect, a prophylactic vaccine, high patient enrollment similar to a COVID vaccine with low doses per year. Also, the mRNA per dose is low, and because of batch pricing, the value that we assign to such a program is on the lower side.
As you step up to personalized medicine and cancer vaccines, the patients per year is lower than a prophylactic vaccine, but the number of doses are significantly higher, and the mRNA per dose, given that there are multiple doses, represents a medium opportunity based on the price and premium we can command there. Likewise, for an mRNA therapeutic, the doses per year now are pretty high, and the mRNA per dose is even higher than a cancer vaccine, and then the price per unit is the highest in terms of opportunity for the company. Likewise, in in vivo gene editing, high patients enrolled, the mRNA doses is pretty high, and again, we've got opportunity to realize price, giving it a high value. Then ex vivo cell therapy is about a medium based on the number of patients that would be enrolled.
So estimated commercial peak by modality, again, $5 million on the low side for something like a prophylactic vaccine, and up to $50 million plus per program for the rest of the modalities. As we think about the pipeline in terms of where our pipeline is in terms of phase and modality, the current program mix is 40% in phase I, 40% in phase I and II, and phase II or phase III is about 20%. Then as you look to the right, like I mentioned, 50 GMP customers in 2026, average of two to three programs per GMP customer, so that gives you a little bit of context on the shots at goal we have and the diversity of programs. Then majority of our pipeline is for the high-value modalities, so 75% plus is in those categories outside of prophylactic vaccines.
I'll just close it out by talking a little bit about programs that are in the clinic today. They, of course, use CleanCap, but programs that enter the clinic now, they also leverage both our ModTail and GMP enzymes, which gives us even more opportunity to carry those GMP products and therefore realize into higher revenue streams.
So with that, Dan? Yeah, that's a nice breakdown.
I think people have been finding the way in which you've been describing the makeup of the businesses to be super helpful just in terms of trying to understand what has been and what might be going forward. So, thank you for those.
Yeah. Maybe just as an overall statement, Raj, to start, 2026 has been a more consistent year for Maravai.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
